IMVT
Immunovant, Inc.
October 8, 2026 · pre-market open
- Rarity
- 1.64
- Peak move
- −6.99%
- Float cap
- $2.6B
Immunovant is a clinical-stage immunology company developing IMVT-1402 (imeroprubart), an anti-FcRn antibody for autoimmune diseases driven by pathogenic IgG antibodies. It is evaluating the candidate in patients with conditions such as Graves' disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, rheumatoid arthritis, Sjögren's disease, and cutaneous lupus erythematosus.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
4 events · 0 from SEC or newswire · 0 timed with the movepeer_disclosureArgenx discontinued its Phase 3 UNITY trial of subcutaneous efgartigimod (Vyvgart Hytrulo) in moderate-to-severe Sjögren's disease after an independent data monitoring committee recommended stopping for futility at an interim analysis, with no new safety signals; Immunovant has an ongoing Phase 2b Sjögren's study of IMVT-1402.
analyst_ratingH.C. Wainwright analyst Douglas Tsao said the argenx Phase 3 UNITY Sjögren's futility finding makes the firm more cautious on the read-through to Immunovant's IMVT-1402 Phase 2b Sjögren's disease study.
investigative_reportCoverage reported the launch of multiple legal probes into how Immunovant communicated the IMVT-1402 cutaneous lupus proof-of-concept trial disappointment, with Levi & Korsinsky LLP opening a securities investigation and Bronstein, Gewirtz & Grossman encouraging investors to assist its investigation.
insider_saleImmunovant CEO and director Eric Venker settled 92,187 Capped Value Appreciation Rights at a $14.46 hurdle on Oct 1, 2026, acquired the resulting shares, disposed of 85,886 shares at $33.65, and sold 3,506 shares at $34.11 on Oct 2 to cover tax withholding via a mandated sell-to-cover, leaving him 257,075 shares.